MAM‐stabilizing S1R is emerging as a unique therapeutic target for AD, with small molecule modulators exhibiting favorable safety profiles and anti‐amnestic effects in mild‐to‐moderate AD.11, 12, 13, 14, 15, 16. This evidence concerns the gene TMBIM4 and Alzheimer disease.